UB Paderborn / Katalog / Suche / in CDI

Design and optimization of highly-selective fungal CYP51 inhibitors

Bioorganic & medicinal chemistry letters, 2014-08, Vol.24 (15), p.3455-3458

2014

Volltextzugriff (PDF)

Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors

Bioorganic & medicinal chemistry letters, 2014-06, Vol.24 (11), p.2444-2447

2014

Volltextzugriff (PDF)

VT-1161 protects mice against oropharyngeal candidiasis caused by fluconazole-susceptible and -resistant Candida albicans

Journal of antimicrobial chemotherapy, 2018-01, Vol.73 (1), p.151-155

2018

Volltextzugriff (PDF)

Development of Highly Selective Pyrimidine-Based Aldosterone Synthase (CYP11B2) Inhibitors

ACS medicinal chemistry letters, 2019-07, Vol.10 (7), p.1056-1060

2019

Volltextzugriff (PDF)

Structural analyses of Candida albicans sterol 14α-demethylase complexed with azole drugs address the molecular basis of azole-mediated inhibition of fungal sterol biosynthesis

The Journal of biological chemistry, 2017-04, Vol.292 (16), p.6728-6743

2017

Volltextzugriff (PDF)

Tribute to a living legend

Current medicinal chemistry, 2012, Vol.19 (25), p.4207

2012

Volltextzugriff (PDF)

Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors

Bioorganic & medicinal chemistry letters, 2017-08, Vol.27 (15), p.3243-3248

2017

Volltextzugriff (PDF)

Crystal Structure of the New Investigational Drug Candidate VT-1598 in Complex with Aspergillus fumigatus Sterol 14α-Demethylase Provides Insights into Its Broad-Spectrum Antifungal Activity

Antimicrobial agents and chemotherapy, 2017-07, Vol.61 (7)

2017

Volltextzugriff (PDF)

In Vitro Activities of the Novel Investigational Tetrazoles VT-1161 and VT-1598 Compared to the Triazole Antifungals against Azole-Resistant Strains and Clinical Isolates of Candida albicans

Antimicrobial agents and chemotherapy, 2019-06, Vol.63 (6)

2019

Volltextzugriff (PDF)

The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii

Antimicrobial agents and chemotherapy, 2016-04, Vol.60 (4), p.2528-2531

2016

Volltextzugriff (PDF)

Impact of the Major Candida glabrata Triazole Resistance Determinants on the Activity of the Novel Investigational Tetrazoles VT-1598 and VT-1161

Antimicrobial agents and chemotherapy, 2019-10, Vol.63 (10)

2019

Volltextzugriff (PDF)

The Investigational Drug VT-1129 Is a Highly Potent Inhibitor of Cryptococcus Species CYP51 but Only Weakly Inhibits the Human Enzyme

Antimicrobial agents and chemotherapy, 2016-08, Vol.60 (8), p.4530-4538

2016

Volltextzugriff (PDF)

In Vivo Efficacy of VT-1129 against Experimental Cryptococcal Meningitis with the Use of a Loading Dose-Maintenance Dose Administration Strategy

Antimicrobial agents and chemotherapy, 2018-11, Vol.62 (11)

2018

Volltextzugriff (PDF)

VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection

Antimicrobial agents and chemotherapy, 2015-12, Vol.59 (12), p.7815-7817

2015

Volltextzugriff (PDF)

Prophylactic Treatment with VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection

Antimicrobial agents and chemotherapy, 2017-09, Vol.61 (9)

2017

Volltextzugriff (PDF)

Efficacy of the Investigational Antifungal VT-1161 in Treating Naturally Occurring Coccidioidomycosis in Dogs

Antimicrobial agents and chemotherapy, 2017-05, Vol.61 (5)

2017

Volltextzugriff (PDF)

The Fungal Cyp51 Inhibitor VT-1129 Is Efficacious in an Experimental Model of Cryptococcal Meningitis

Antimicrobial agents and chemotherapy, 2018-09, Vol.62 (9)

2018

Volltextzugriff (PDF)

Activity of VT-1129 against Cryptococcus neoformans clinical isolates with high fluconazole MICs

Medical mycology (Oxford), 2017-06, Vol.55 (4), p.453-456

2017

Volltextzugriff (PDF)

Evaluation of VT-1161 for Treatment of Coccidioidomycosis in Murine Infection Models

Antimicrobial agents and chemotherapy, 2015-12, Vol.59 (12), p.7249-7254

2015

Volltextzugriff (PDF)

The Tetrazole VT-1161 Is a Potent Inhibitor of Trichophyton rubrum through Its Inhibition of T. rubrum CYP51

Antimicrobial agents and chemotherapy, 2017-07, Vol.61 (7)

2017

Volltextzugriff (PDF)

Clinical Candidate VT-1161's Antiparasitic Effect In Vitro, Activity in a Murine Model of Chagas Disease, and Structural Characterization in Complex with the Target Enzyme CYP51 from Trypanosoma cruzi

Antimicrobial agents and chemotherapy, 2016-02, Vol.60 (2), p.1058-1066

2016

Volltextzugriff (PDF)

Discovery of Novel Quinoline-Based Estrogen Receptor Ligands Using Peptide Interaction Profiling

Journal of medicinal chemistry, 2005-03, Vol.48 (6), p.2243-2247

2005

Volltextzugriff (PDF)

Potent, Orally Active GPIIb/IIIa Antagonists Containing a Nipecotic Acid Subunit. Structure−Activity Studies Leading to the Discovery of RWJ-53308

Journal of medicinal chemistry, 1999-12, Vol.42 (25), p.5254-5265

1999

Volltextzugriff (PDF)

Recent advances in peroxisome proliferator-activated receptor science

Current medicinal chemistry, 2003-02, Vol.10 (4), p.267

2003

Volltextzugriff (PDF)

Direct effects of the selective CYP17 lyase (L) inhibitor, VT-464, on the androgen receptor (AR) and its oral activity in an F876L tumor mouse xenograft model

Journal of clinical oncology, 2015-03, Vol.33 (7_suppl), p.263-263

2015

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Design and optimization of highly-selective fungal CYP51 inhibitors

Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors

VT-1161 protects mice against oropharyngeal candidiasis caused by fluconazole-susceptible and -resistant Candida albicans

Development of Highly Selective Pyrimidine-Based Aldosterone Synthase (CYP11B2) Inhibitors

Structural analyses of Candida albicans sterol 14α-demethylase complexed with azole drugs address the molecular basis of azole-mediated inhibition of fungal sterol biosynthesis

Tribute to a living legend

Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors

Crystal Structure of the New Investigational Drug Candidate VT-1598 in Complex with Aspergillus fumigatus Sterol 14α-Demethylase Provides Insights into Its Broad-Spectrum Antifungal Activity

In Vitro Activities of the Novel Investigational Tetrazoles VT-1161 and VT-1598 Compared to the Triazole Antifungals against Azole-Resistant Strains and Clinical Isolates of Candida albicans

The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii

Impact of the Major Candida glabrata Triazole Resistance Determinants on the Activity of the Novel Investigational Tetrazoles VT-1598 and VT-1161

The Investigational Drug VT-1129 Is a Highly Potent Inhibitor of Cryptococcus Species CYP51 but Only Weakly Inhibits the Human Enzyme

In Vivo Efficacy of VT-1129 against Experimental Cryptococcal Meningitis with the Use of a Loading Dose-Maintenance Dose Administration Strategy

VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection

Prophylactic Treatment with VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection

Efficacy of the Investigational Antifungal VT-1161 in Treating Naturally Occurring Coccidioidomycosis in Dogs

The Fungal Cyp51 Inhibitor VT-1129 Is Efficacious in an Experimental Model of Cryptococcal Meningitis

Activity of VT-1129 against Cryptococcus neoformans clinical isolates with high fluconazole MICs

Evaluation of VT-1161 for Treatment of Coccidioidomycosis in Murine Infection Models

The Tetrazole VT-1161 Is a Potent Inhibitor of Trichophyton rubrum through Its Inhibition of T. rubrum CYP51

Clinical Candidate VT-1161's Antiparasitic Effect In Vitro, Activity in a Murine Model of Chagas Disease, and Structural Characterization in Complex with the Target Enzyme CYP51 from Trypanosoma cruzi

Discovery of Novel Quinoline-Based Estrogen Receptor Ligands Using Peptide Interaction Profiling

Potent, Orally Active GPIIb/IIIa Antagonists Containing a Nipecotic Acid Subunit. Structure−Activity Studies Leading to the Discovery of RWJ-53308

Recent advances in peroxisome proliferator-activated receptor science

Direct effects of the selective CYP17 lyase (L) inhibitor, VT-464, on the androgen receptor (AR) and its oral activity in an F876L tumor mouse xenograft model

Suchergebnisse filtern